Nanjing King-Friend Biochemical Pharmaceutical (603707) Stock Overview

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. The company provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium, cisatracurium, fulvestrant, doxercalciferol, milrinone lactate, fondaparinux sodium, phenylephrine, gemcitabine, levoleucovorin, carboplatin, cytarabine, bleomycin, topotecan hydrochloride, bendamustine HCL, bortezomib, clofarabine, busulfan, dactinomycin, azacitidine, mycophenolate mofetil, tigecycline, glycopyrrolate, melphalan, daptomycin, decitabine, haloperidol decanoate, carmustine, bivalirudin, dexmedetomidine, and neostigmine methylsulfate injections. It also offers isosulfan blue, succinylcholine chloride, furosemide, regadenoson, voriconazole, ganirelix acetate, eptifibatide, enoxaparin sodium, mitomycin, vancomycin, micafungin sodium, docetaxel, nelarabine, pemetrexed, rocuronium bromide, zoledronic acid, thiamine, fluorouracil, perixafor, thiotepa, pantoprazole sodium, glatiramer acetate, and bupivacaine hydrochloride injections. The company was founded in 2000 and is based in Nanjing, China.